Phase 2 study of Civamide Patch for post-herpetic neuralgia (PHN)

Winston Laboratories announced positive top-line results from Study WL1001-04-03, a Phase 2 clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide in the treatment of post-herpetic neuralgia (PHN). Study WL1001-04-03 was an open-label multi-center study of 20 patients with chronic, intractable PHN, unresponsive or poorly responsive to standard oral therapies, and was designed to evaluate the safety and efficacy of Civamide Patch 0.015%. In this study, a single patch was applied once daily to the area of the trunk affected by PHN and worn for 12 to 24 hours before replacing with a new patch during the 28 day treatment duration. The study successfully demonstrated the efficacy of Civamide Patch 0.015% in reducing pain and improving sleep in as little as one week of applying the patch to the skin affected by PHN with 40% or greater improvement in both parameters at the end of the 4 week study.

Civamide is a novel TRPV-1 receptor modulator being developed for the treatment of post-herpetic neuralgia (PHN), the chronic pain persisting for at least 3 months after a herpes zoster eruption (commonly referred to as "shingles").

For more information call (847) 362-8200 or visit www.winstonlabs.com.